Prothena Corporation plc (PRTA)
Prothena Posts Q1 Earnings as Revenues Surge on Milestone Payment
PRTA posted a Q1 profit as a $50M Novo Nordisk milestone payment boosted revenue and improved its 2026 cash outlook.
Wall Street Analysts Think Prothena (PRTA) Could Surge 120.19%: Read This Before Placing a Bet
The mean of analysts' price targets for Prothena (PRTA) points to a 120.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Prothena: A Hold With 2 Late-Stage Programs Underway But With Caution
Prothena Corporation plc is maintained at a Hold rating due to mixed phase 2 data and long timelines for key programs. PRTA's leading assets, prasinezumab (Parkinson's disease) and coramitug (ATTR-CM), are in phase 3 trials with primary completion expected in 2029. The Bristol-Myers Squibb partnership provides up to $1.55 billion in milestones and royalties, with BMS-986446 in phase 2 for early Alzheimer's.
Wall Street Analysts Believe Prothena (PRTA) Could Rally 118.09%: Here's is How to Trade
The consensus price target hints at an 118.1% upside potential for Prothena (PRTA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus
PRTA posts a narrower year-over-year Q4 loss. Revenues miss estimates, as it outlines 2026 cash burn guidance and eyes key milestones from partners.
Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript
Prothena Corporation plc (PRTA) Q4 2025 Earnings Call Transcript
Prothena (PRTA) Reports Q4 Loss, Lags Revenue Estimates
Prothena (PRTA) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $1.08 per share a year ago.
Prothena Stock Tumbles 36.8% Year Over Year: What Lies Ahead?
PRTA stock declines 36.8% in a year as birtamimab's failure, earnings miss and reliance on partner programs weigh on investor confidence.
All You Need to Know About Prothena (PRTA) Rating Upgrade to Buy
Prothena (PRTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Prothena Q3 Earnings Miss Estimates, Pipeline Progress in Focus
Prothena's Q3 loss widened as revenues fell short of estimates, but its Alzheimer and Parkinson's drug programs gained FDA momentum and key collaborations advanced.
Prothena (PRTA) Reports Q3 Loss, Lags Revenue Estimates
Prothena (PRTA) came out with a quarterly loss of $0.67 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $1.1 per share a year ago.
Prothena Down 40% Year to Date: What Lies Ahead for the Stock?
Prothena stock tumbles 40% year to date due to pipeline setbacks, though its partnered programs with Roche and Novo Nordisk still show potential.
